Discover the full record of transactions filed by Schroeder Theodore R, Former Chief Executive Officer. Officer active across 1 companies, notably Nabriva Therapeutics plc. Cumulatively, 53 reports have been published. Total volume traded: €197k. The latest transaction was filed on 30 June 2022 — Retenue fiscale. Regulator: SEC (Form 4). All data is free.
25 of 53 declarations
Theodore R. Schroeder is an experienced biopharmaceutical executive best known for his recent leadership role as Chief Executive Officer of Nabriva Therapeutics plc, where he also served on the board of directors. SEC filings indicate that he assumed that role in July 2018, following Nabriva’s acquisition of Zavante Therapeutics. His career spans more than 30 years focused on drug development and commercialization across both large pharmaceutical companies and smaller, innovation-driven biotech firms. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641640/000110465921088033/tm2119969-2_def14a.htm?utm_source=openai)) Prior to Nabriva, Mr. Schroeder served as President, Chief Executive Officer, and a director of Zavante Therapeutics from June 2015 to July 2018. He also co-founded Cadence Pharmaceuticals in 2004 and served as its President and Chief Executive Officer, and as a board member, until Cadence was acquired by Mallinckrodt in 2014. That Cadence tenure is a defining part of his background, reflecting his ability to build and scale a biopharma company through to a strategic exit. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641640/000110465921088033/tm2119969-2_def14a.htm?utm_source=openai)) Earlier in his career, he held senior leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals, and Bristol-Myers Squibb, gaining deep experience in hospital marketing, commercial strategy, and pharmaceutical operations. Public company biographies also highlight his governance background: he has served on the boards of Cidara Therapeutics, Otonomy, and Collegium Pharmaceutical, along with other life sciences companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641640/000110465921088033/tm2119969-2_def14a.htm?utm_source=openai)) Notable achievements include leading companies through major acquisitions, helping establish leadership teams in the anti-infectives space, and earning industry recognition. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was also a national finalist. He holds a bachelor’s degree in management from Rutgers University. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641640/000110465921088033/tm2119969-2_def14a.htm?utm_source=openai))